Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540837 | 0.93 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CMAPTSMN1; SMN2 | |
| SCHEMBL592019 | 0.93 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CMAPTSMN1; SMN2 | |
| SCHEMBL21124236 | 0.88 | MAPT (0.49) | ADRA2AADRA2BADRA2CMAPTSMN1; SMN2 | |
| SCHEMBL29648863 | 0.85 | HTR3E (0.53) | ADRA2AADRA2BADRA2CMAPTSMN1; SMN2 | |
| SCHEMBL140824 | 0.85 | HTR3E (0.53) | ADRA2AADRA2BADRA2CMAPTSMN1; SMN2 | |
| SCHEMBL26323681 | 0.81 | DYRK1A (0.43) | MAPK1TDP1CYP3A4TRPA1ERN1 | |
| SCHEMBL1019306 | 0.77 | PRKCI (0.44) | ADRA2AADRA2BADRA2CMAPTSMN1; SMN2 | |
| SCHEMBL276124 | 0.74 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CMAPTSMN1; SMN2 | |
| SCHEMBL97119 | 0.72 | NPC1 (0.45) | MAPTSMN1; SMN2ALDH1A1TDP1NPC1 | |
| SCHEMBL14256915 | 0.71 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3296309-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3296309-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit Gent (BE) | 2018-03-21 | — | — | EP | disclosed |
| EP-2877480-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-9321796-B2 | Galactopyranosyl derivatives useful as medicaments | UNIVERSITEIT GENT (BE) | 2016-04-26 | — | — | US | disclosed |
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | AMBICION CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2877480-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit van Gent (BE) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014001204-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIVERSITEIT GENT (BE) | 2014-01-03 | — | — | WO | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009003669-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-01-08 | — | — | WO | disclosed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | disclosed |
| EP-1981504-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV Remynd (BE) | 2008-10-22 | — | — | EP | disclosed |
| EP-1960365-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Unibioscreen S.A. (BE) | 2008-08-27 | — | — | EP | disclosed |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2008-08-21 | — | — | US | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | ADRA2A 178/4885ADRA2B 179/4885ADRA2C 57/4885 |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRA2A 3899/4885ADRA2B 4028/4885ADRA2C 3536/4885 |
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | B3GAT3, GALR3, ST6GAL1 | ADRA2A 2262/4885ADRA2B 1138/4885ADRA2C 889/4885 |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | DCTD, DHODH, DHRS9 | ADRA2A 1747/4885ADRA2B 1282/4885ADRA2C 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.